The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Troglitazone Inhibits Formation of Early Atherosclerotic Lesions in Diabetic and Nondiabetic Low Density Lipoprotein Receptor–Deficient Mice
Abstract
Abstract —Peroxisome proliferator–activated receptor-γ (PPARγ) is a ligand-activated nuclear receptor expressed in all of the major cell types found in atherosclerotic lesions: monocytes/macrophages, endothelial cells, and smooth muscle cells. In vitro, PPARγ ligands inhibit cell proliferation and migration, 2 processes critical for vascular lesion formation. In contrast to these putative antiatherogenic activities, PPARγ has been shown in vitro to upregulate the CD36 scavenger receptor, which could promote foam cell formation. Thus, it is unclear what impact PPARγ activation will have on the development and progression of atherosclerosis. This issue is important because thiazolidinediones, which are ligands for PPARγ, have recently been approved for the treatment of type 2 diabetes, a state of accelerated atherosclerosis. We report herein that the PPARγ ligand, troglitazone, inhibited lesion formation in male low density lipoprotein receptor–deficient mice fed either a high-fat diet, which also induces type 2 diabetes, or a high-fructose diet. Troglitazone decreased the accumulation of macrophages in intimal xanthomas, consistent with our in vitro observation that troglitazone and another thiazolidinedione, rosiglitazone, inhibited monocyte chemoattractant protein-1–directed transendothelial migration of monocytes. Although troglitazone had some beneficial effects on metabolic risk factors (in particular, a reduction of insulin levels in the diabetic model), none of the systemic cardiovascular risk factors was consistently improved in either model. These observations suggest that the inhibition of early atherosclerotic lesion formation by troglitazone may result, at least in part, from direct effects of PPARγ activation in the artery wall.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Virmani, R., Kolodgie, F. D., Burke, A. P., Farb, A., & Schwartz, S. M. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.5.1262 · Cited by 4,084
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420302 · Cited by 1,957
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797
ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.
Nakashima, Y., Plump, A. S., Raines, E. W., Breslow, J. L., & Ross, R. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.1.133 · Cited by 1,693
Gu, L., Okada, Y., Clinton, S. K., Gerard, C., Sukhova, G. K., Libby, P., & Rollins, B. J. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80139-2 · Cited by 1,575
Atherosclerosis is an inflammatory disease
Ross, R. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70266-8 · Cited by 1,451
Kelley, D. E., Goodpaster, B., Wing, R. R., & Simoneau, J.-A. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.6.e1130 · Cited by 1,096
Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes
Saltiel, A. R., & Olefsky, J. M. (1996) · Diabetes · doi:10.2337/diab.45.12.1661 · Cited by 1,053
Li, A. C., Brown, K. K., Silvestre, M. J., Willson, T. M., Palinski, W., & Glass, C. K. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10370 · Cited by 833
Self-citationRicote, M., Huang, J., Fajas, L., Li, A., Welch, J., Najib, J., Witztum, J. L., Auwerx, J., Palinski, W., & Glass, C. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7614 · Cited by 721
Self-citationMarx, N., Schönbeck, U., Lazar, M. A., Libby, P., & Plutzky, J. (1998) · Circulation Research · doi:10.1161/01.res.83.11.1097 · Cited by 587
Tangirala, R. K., Rubin, E. M., & Palinski, W. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39713-3 · Cited by 514
Self-citationXin, X., Yang, S., Kowalski, J., & Gerritsen, M. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.9116 · Cited by 513
Pasceri, V., Wu, H. D., Willerson, J. T., & Yeh, E. T. H. (2000) · Circulation · doi:10.1161/01.cir.101.3.235 · Cited by 504
Praticò, D., Tangirala, R. K., Rader, D. J., Rokach, J., & FitzGerald, G. A. (1998) · Nature Medicine · doi:10.1038/2685 · Cited by 501
Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.
Law, R. E., Meehan, W. P., Xi, X. P., Graf, K., Wuthrich, D. A., Coats, W., Faxon, D., & Hsueh, W. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118991 · Cited by 476
Self-citationExpression and Function of PPARγ in Rat and Human Vascular Smooth Muscle Cells
Law, R. E., Goetze, S., Xi, X.-P., Jackson, S., Kawano, Y., Demer, L., Fishbein, M. C., Meehan, W. P., & Hsueh, W. A. (2000) · Circulation · doi:10.1161/01.cir.101.11.1311 · Cited by 442
Self-citationMetabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects
Suter, S. L., Nolan, J. J., Wallace, P., Gumbiner, B., & Olefsky, J. M. (1992) · Diabetes Care · doi:10.2337/diacare.15.2.193 · Cited by 420
Jackson, S. M., Parhami, F., Xi, X.-P., Berliner, J. A., Hsueh, W. A., Law, R. E., & Demer, L. L. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.9.2094 · Cited by 373
Self-citationTowler, D. A., Bidder, M., Latifi, T., Coleman, T., & Semenkovich, C. F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30427 · Cited by 246
Heterogeneity of pig intestinal d-glucose transport systems
Halaihel, N., Gerbaud, D., Vasseur, M., & Alvarado, F. (1999) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1999.277.6.c1130 · Cited by 199
Takagi, T., Akasaka, T., Yamamuro, A., Honda, Y., Hozumi, T., Morioka, S., & Yoshida, K. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00895-0 · Cited by 187
Goetze, S., Xi, X.-P., Kawano, H., Gotlibowski, T., Fleck, E., Hsueh, W. A., & Law, R. E. (1999) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199905000-00018 · Cited by 187
Self-citationTack, C. J. J., Ong, M. K. E., Lutterman, J. A., & Smits, P. (1998) · Diabetologia · doi:10.1007/s001250050948 · Cited by 177
Merat, S., Casanada, F., Sutphin, M., Palinski, W., & Reaven, P. D. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.5.1223 · Cited by 160
Self-citationDietary Antioxidants Inhibit Development of Fatty Streak Lesions in the LDL Receptor–Deficient Mouse
Crawford, R. S., Kirk, E. A., Rosenfeld, M. E., LeBoeuf, R. C., & Chait, A. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.9.1506 · Cited by 118
Savage, P. J. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-1_part_2-199601011-00008 · Cited by 111
Troglitazone Has a Scavenging Effect on Reactive Oxygen Species
Inoue, I., Katayama, S., Takahashi, K., Negishi, K., Miyazaki, T., Sonoda, M., & Komoda, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6512 · Cited by 96
Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes
Kawai, T., Takei, I., Oguma, Y., Ohashi, N., Tokui, M., Oguchi, S., Katsukawa, F., Hirose, H., Shimada, A., Watanabe, K., et al. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90122-1 · Cited by 93
Sung, B. H., Izzo, J. L., Dandona, P., & Wilson, M. F. (1999) · Hypertension · doi:10.1161/01.hyp.34.1.83 · Cited by 91
Yoshimoto, T., Naruse, M., Shizume, H., Naruse, K., Tanabe, A., Tanaka, M., Tago, K., Irie, K., Muraki, T., Demura, H., et al. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00085-4 · Cited by 85
Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice
Bird, D. A., Tangirala, R. K., Fruebis, J., Steinberg, D. H., Witztum, J. L., & Palinski, W. (1998) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33877-3 · Cited by 81
Self-citationMurakami, T., Mizuno, S., Ohsato, K., Moriuchi, I., Arai, Y., Nio, Y., Kaku, B., Takahashi, Y., & Ohnaka, M. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00199-x · Cited by 78
Altered Pressure-Natriuresis in Obese Zucker Rats
Fujiwara, K., Hayashi, K., Matsuda, H., Kubota, E., Honda, M., Ozawa, Y., & Saruta, T. (1999) · Hypertension · doi:10.1161/01.hyp.33.6.1470 · Cited by 69
Shaish, A., George, J., Gilburd, B., Keren, P., Levkovitz, H., & Harats, D. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.6.1470 · Cited by 58
Goetze, S., Xi, X.-P., Graf, K., Fleck, E., Hsueh, W. A., & Law, R. E. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00624-9 · Cited by 56
Self-citationChen, S., Noguchi, Y., Izumida, T., Tatebe, J., & Katayama, S. (1996) · Journal of Hypertension · doi:10.1097/00004872-199611000-00011 · Cited by 40
Shi, C., Lee, W., Russell, M. E., Zhang, D., Fletcher, D. L., Newell, J. B., & Haber, E. (1997) · Circulation · doi:10.1161/01.cir.96.8.2722 · Cited by 39
Cited by
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Michalik, L., Auwerx, J., Berger, J. P., Chatterjee, V. K., Glass, C. K., Gonzalez, F. J., Grimaldi, P. A., Kadowaki, T., Lazar, M. A., O’Rahilly, S., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.5 · Cited by 1,000
Synthetic LXR ligand inhibits the development of atherosclerosis in mice
Joseph, S. B., McKilligin, E., Pei, L., Watson, M. A., Collins, A. R., Laffitte, B. A., Chen, M., Noh, G., Goodman, J., Hagger, G. N., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.112059299 · Cited by 947
Self-citationVarga, T., Czimmerer, Z., & Nagy, L. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.02.014 · Cited by 933
Metadata
- Authors
- Collins, A. R., Meehan, W. P., Kintscher, U., Jackson, S., Wakino, S., Noh, G., Palinski, W., Hsueh, W. A., & Law, R. E.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2001-03
- Volume
- 21
- Issue
- 3
- Pages
- 365-371
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W1968243232
- Cited by
- 385
- References
- 39
- FWCI
- 15.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.